The Seer spinoff recently closed a $46 million funding round that it is using to support efforts in nucleic acid, proteomic, and metabolomic biomarker discovery.
Read the full article here.
June 21, 2022
PrognomiQ partners with KSM to discover cancer biomarkers
March 15, 2022
PrognomiQ lands $46M from Bruker for multiomics platform